Published in J Clin Microbiol on October 01, 2006
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol (2008) 0.96
Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol (2009) 0.92
Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer (2010) 0.88
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol (2014) 0.85
Interlaboratory reproducibility and proficiency testing within the human papillomavirus cervical cancer screening program in Catalonia, Spain. J Clin Microbiol (2014) 0.84
Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer (2013) 0.83
The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. J Clin Microbiol (2016) 0.82
Triage of high-risk human papillomavirus-positive women by methylated POU4F3. Clin Epigenetics (2015) 0.82
Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia. Infect Agent Cancer (2014) 0.78
Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays. BMC Infect Dis (2013) 0.76
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA (2002) 15.59
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer (2003) 2.53
Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2002) 2.24
The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer (2003) 1.90
Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol (2004) 1.82
PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol (2000) 1.73
Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer (2006) 1.56
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer (2005) 1.55
Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol (2001) 1.49
Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol (2004) 1.33
Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med (2003) 1.32
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol (2005) 1.20
High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol (2001) 1.12
HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv (2004) 1.10
Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods (2004) 0.92
Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol (2005) 0.89
Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol (2004) 0.88
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62
Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol (1995) 3.59
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. J Virol (1986) 2.93
The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol (2004) 2.63
Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 2.56
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer (2002) 2.25
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
Comparison of Southern blot hybridization and polymerase chain reaction methods for the detection of human papillomavirus DNA. J Clin Microbiol (1991) 2.19
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect (2002) 2.05
Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol (2006) 2.02
Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol (1994) 2.00
Nucleotide sequence of human papillomavirus type 31: a cervical neoplasia-associated virus. Virology (1989) 1.95
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer (2006) 1.83
Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer (2002) 1.83
Papillomavirus infection in rural women in southern India. Br J Cancer (2005) 1.79
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol (2004) 1.63
Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer (2006) 1.62
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
Collection devices for human papillomavirus. J Fam Pract (1999) 1.57
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica. Cancer (1998) 1.54
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
A new type of papillomavirus associated with cancer of the uterine cervix. Virology (1987) 1.53
Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol (1988) 1.52
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer (2001) 1.52
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer (2009) 1.50
Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol (2011) 1.47
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol (2006) 1.46
Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer (2006) 1.43
A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol (2004) 1.43
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol (2002) 1.36
Validation of high-risk HPV tests for primary cervical screening. J Clin Virol (2009) 1.35
[Vaccines against human papillomavirus (HPV); between registration and implementation]. Ned Tijdschr Geneeskd (2008) 1.34
Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer (2012) 1.34
[Flat penile lesions in the sexual transmission of human papillomavirus]. Ned Tijdschr Geneeskd (2008) 1.32
Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer (2007) 1.32
Characterization of human papillomavirus type 45, a new type 18-related virus of the genital tract. J Gen Virol (1987) 1.32
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol (2014) 1.30
Evaluating an educational intervention to improve the treatment of asthma in four European countries. Drug Education Project Group. Am J Respir Crit Care Med (1999) 1.28
Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol (2008) 1.28
Effects of stressful daily events on mood states: relationship to global perceived stress. J Pers Soc Psychol (1998) 1.28
Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology (2006) 1.28
Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract (1998) 1.27
Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect (2005) 1.26
Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol (2003) 1.25
High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer (2007) 1.24
Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol (2005) 1.20
Possible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol (1988) 1.18
Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract (1998) 1.17
Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer (2008) 1.17
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer (2008) 1.16
Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev (1998) 1.16